A Mendelian randomization study investigating the role of sleep traits and their joint effects on the incidence of atrial fibrillation

Nikhil Arora[1,2*], Ben Michael Brumpton[1,3,4], Bjørn Olav Åsvold[1,3,5], Jan Pål Loennechen[6,7], Vegard Malmo[6,7], Laxmi Bhatta[1,8,9], Eivind Schjelderup Skarpsno[10,11], Rebecca Claire Richmond[2,12,13†] and Linn Beate Strand[10†]

[1]HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; [2]Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom; [3]HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Levanger, Norway; [4]Department of Medicine, St. Olavs Hospital, Trondheim, Norway; [5]Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim, Norway; [6]Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; [7]Clinic of Cardiology, St. Olavs Hospital, Trondheim, Norway; [8]FIU-PH, Division of Mental Health Care, St. Olavs Hospital, Trondheim, Norway; [9]Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; [10]Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; [11]Department of Neurology and Clinical Neurophysiology, St. Olavs Hospital, Trondheim, Norway; [12]MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom; and [13]NIHR Oxford Health Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

[*] Corresponding author: e-mail nikhil.arora@ntnu.no, or docnikhilarora@gmail.com
[†] These authors contributed equally to this work: Rebecca Claire Richmond and Linn Beate Strand

Abstract

Background and Aims: Sleep disturbances can induce alterations in functional and electrical properties of the heart, thereby increasing susceptibility to atrial fibrillation (AF). We aimed to test the causal role of different sleep traits and their joint effects on the risk of AF.

Methods: We used an observational cohort study design along with one-sample and factorial Mendelian randomization (MR) approaches to test for individual and joint associations of sleep traits (i.e., insomnia symptoms, sleep duration and chronotype) on the risk of AF using UK Biobank and the second survey of the Trøndelag Health Study (HUNT2).

Results: Both the observational and the MR analysis showed that insomnia symptoms and genetic predisposition to insomnia symptoms increased risk of AF; however these MR findings were not consistent in HUNT2. One-sample MR analysis in UK Biobank showed that genetic predisposition to short sleep duration increased risk of AF and genetic predisposition to per additional hour of sleep decreased risk of AF; however these findings were not consistent in HUNT2 or in observational analysis. Factorial MR analysis in UK Biobank showed that participants with genetic predisposition to two sleep traits in combination (including insomnia symptoms, short sleep duration, and a morning chronotype) had higher risk of AF than those with genetic predisposition to only one sleep trait; however these findings were not consistent in HUNT2 or in observational analysis. We found no evidence of relative excess risk due to interaction (RERI) for any combinations of sleep traits.

Conclusions: Our study indicates that insomnia symptoms and short sleep duration are causal risk factors for AF. However, having two sleep traits in combination did not increase risk beyond the additive risk of each individual trait. This reinforces clinical and public health efforts to effectively manage insomnia symptoms and short sleep, in order to mitigate the risk of AF and improve overall cardiovascular health.

Keywords: Atrial fibrillation, insomnia, sleep duration, chronotype and Mendelian randomization.

Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrythmia, estimated to have affected 59.7 million individuals globally by 2019.[1] Accompanying the population aging in the west and improved survival with chronic ailments, AF is emerging as a global epidemic.[2,3] AF is linked with increased morbidity, mortality and substantial healthcare expenditures,[4,5] underpinning the need for research efforts aimed at identifying modifiable risk factors that can be targeted to improve prevention and treatment strategies.

Sleep is acknowledged as an essential modulator of cardiovascular function, possibly due to autonomic dysregulation and hormonal disturbances.[6,7] Sleep deprivation can increase the QT interval and atrial electromechanical delay,[8,9] suggesting that it may induce changes in functional and electrical properties of the heart and promote the occurrence of arrythmias. A previous observational study identified insomnia as an individual risk factor for AF (hazard ratio (HR) 1.14; 95% confidence interval (CI) 1.08, 1.21).[10] Moreover, a meta-analysis on cohort studies provided strong evidence that short (≤6 h) and long (≥9 h) sleep durations were associated with increased risk of AF (HR 1.21; 95% CI 1.02, 1.44 and HR 1.18; 95% CI 1.03, 1.35, respectively).[11] While studies found increased risk of myocardial infarction in people with evening chronotype (characterized by staying up late and/or waking up late),[12,13] no study has examined potential impact of chronotype on the risk of AF.

Sleep is a complex and multifaceted biological phenomenon comprising several traits.[14] Some studies have found evidence that sleep traits interact to increase the risk of cardiovascular outcomes.[12,15–17] In particular, insomnia with short sleep duration, considered the most biologically severe sleep disorder phenotype,[18] has been associated with increased cardiometabolic risk.[19,20] It is therefore plausible that individuals experiencing poor sleep, characterized by a combination of extreme sleep traits, may have higher incidence of AF.

Disentangling causal from spurious associations can be challenging in conventional observational studies of sleep traits due to confounding, reverse causation, and measurement error bias.[21] For example, obesity and smoking status are possible common causes of sleep traits and cardiovascular disease, and not all possible confounders are known or measured. Mendelian randomization (MR) uses genetic variants robustly associated with an exposure (sleep traits) as instrumental variables to investigate causal effects on an outcome (AF).[22] MR relies on the fact that genetic variants are randomly assigned at conception, therefore allocating individuals to the exposure group based on genotype (analogous to treatment assignment in a randomized controlled trial). Given the random and independent assignment of alleles at conception, bias arising from reverse causation can be avoided, and the impact of confounding can be reduced. Moreover, genetically-determined sleep traits may be more reflective of sleep behaviours across the lifespan, thereby decreasing measurement error compared to a single self-reported measurement.[22]

Recent MR studies have suggested that insomnia symptoms have an adverse effect on AF (odds ratio (OR) ranged from 1.04 to 1.13), as did short sleep duration (≤6 h) (OR ranged from 1.11 to 1.13).[23–27] Whereas longer sleep duration had a protective effect on AF (OR ranged from 0.68 to 0.89 per hour increase).[26,27] Chronotype has not been explored in relation to AF using MR. Further, MR investigations are warranted to investigate the joint effects of sleep traits on incidence of AF, which could provide robust evidence on the causal risk of AF from concomitant exposure to two sleep traits.[28]

The aim of this study was to examine association of individual sleep traits (insomnia symptoms, sleep duration and chronotype) and their joint effects on the risk of AF using data from the UK Biobank and the second survey of the Trøndelag Health Study (HUNT2). We compared findings from observational and MR analyses, to determine possible causality of individual sleep traits and their joint effects on the incidence of AF.

Methods

Study design and population

We conducted parallel prospective cohort and factorial MR studies in two large cohorts – UK Biobank (2006-10) and HUNT2 (1995-97). Owing to the non-availability of sleep duration in HUNT1 and HUNT3, and short follow-up in HUNT4, we chose to use HUNT2. Over 500 000 adults (5.5% of the invited) ranging between 40 and 70 years participated in UK Biobank,[29] and 65 228 adults (69.5% of the invited) aged 20 years or older participated in HUNT2.[30] All participants provided written informed consent. The sample in the present study were restricted to participants with European decent, as genetic variants used for MR analyses were investigated in genome-wide association studies (GWAS) with European ancestry. This enabled comparison of observational and MR estimates within the same underlying population. UK Biobank was approved by the National Health Service (NHS) Research Ethics Service (reference number 11/NW/0382). The HUNT Study has ethical clearance from the Data Inspectorate of Norway and HUNT2 was approved by the Regional Committee for Ethics in Medical Research (REK; reference number 152/95/AH/JGE). Approval to conduct this study was also received from the Regional Committee for Ethics in Medical Research (REK nord; reference number 2020/47206).

Sleep traits

Insomnia symptoms

In UK Biobank, participants were asked a single question if they have trouble falling asleep at night or if they wake up in the middle of the night with response options "never/rarely", "sometimes", "usually" or "prefer not to answer". Those who responded "usually" were classified as having insomnia symptoms, and "sometimes" or "never/rarely" as not having insomnia symptoms. Other responses were coded as missing.

In HUNT2, participants were asked two questions: (1) if they had difficulty falling asleep in the last month, and (2) if they have woken too early and not been able to get back to sleep during the last month, both with the response options "never", "sometimes", "often" or "almost every night". Participants who responded "often" or "almost every night" to both of these questions were classified as having insomnia symptoms. For participants who answered only one of these questions, we did the following: (1) if they responded "often" or "almost every night" to one of these, they were classified as having insomnia symptoms, and (2) if they responded "never" or "sometimes" to one of these, but did not answer the other, they were excluded to avoid possible misclassification. The remaining participants were classified as not having insomnia symptoms.

Our definition of insomnia included two night-time insomnia symptoms (i.e., difficulty falling asleep, difficulty maintaining sleep or waking up too early) without information about daytime impairment. Since this definition does not fulfil the clinical criteria to be diagnosed with insomnia,[31] we used the term *insomnia symptoms* throughout this manuscript.

Sleep duration

In UK Biobank, participants were asked about the number of hours of sleep they get every 24 h (including their naps). In HUNT2, participants were asked about the number of hours they usually spend lying down (i.e. sleeping and/or napping) during a 24-h period. In both cohorts, the answers could only contain integer values. Implausible short or long sleep durations were avoided by excluding extreme responses of less than 3 h or more than 18 h. Participants were categorized into normal (7-8 h), short ($\leq$6 h) or long ($\geq$9 h) hours of sleep duration. Binary variables for short ($\leq$6 h vs. 7-8 h) and long ($\geq$9 h vs. 7-8 h) sleep durations were constructed.

Chronotype

Chronotype (diurnal preference) was only reported in UK Biobank. Participants were asked if they consider themselves to be "definitely a 'morning' person", "more a 'morning' than 'evening' person", "more an 'evening' than a 'morning' person", "definitely an 'evening' person", "do not know", or "prefer not to answer". Participants were classified as having a morning chronotype if they reported "definitely a 'morning' person" or "more a 'morning' than 'evening' person", and as having an

evening chronotype if they reported "more an 'evening' than a 'morning' person" or "definitely an 'evening' person". Other responses were coded as missing.

Genetic variants

DNA was extracted from blood samples collected by trained professionals in both cohorts. In UK Biobank, participants were genotyped using either one of the UK BiLEVE or the UK Biobank Axiom genotyping chips. The genetic variants used were from the UK Biobank imputed dataset (merged Haplotype Reference Consortium and UK10K plus 1000 Genomes phase 3 reference panels), that were quality controlled using a standard protocol.[32,33] In HUNT2 and HUNT3, participants were genotyped with one of three different Illumina HumanCoreExome genotyping chips (HumanCoreExome 12 v.1.0, HumanCoreExome 12 v.1.1, and UM HUNT Biobank v.1.0), where genotypes from different chips were quality controlled separately and reduced to a common set of variants. The quality control measures used were similar to UK Biobank.[34]

A total of 248 single nucleotide polymorphisms (SNPs) were identified as robustly associated with insomnia symptoms at $P < 5 \times 10^{-8}$ based on the meta-analysis of UK Biobank (n = 386 533) and 23andMe (n = 944 477) cohorts in a GWAS by Jansen *et al.*[35] A large GWAS performed by Dashti *et al.*[36] based on UK Biobank (n = 446 118) identified 78 SNPs as robustly associated with 24-hour sleep duration. They additionally identified 27 SNPs specific for short and 8 SNPs specific for long sleep duration. A genome-wide association meta-analysis by Jones *et al.*[37] based on UK Biobank (n = 403 195) and 23andMe (n = 248 100) identified 351 SNPs robustly associated with chronotype (morning preference). A comprehensive list with detailed information on discovery GWASs used to obtain the genetic instruments is provided (see supplementary material, Table S1).

Ascertainment of atrial fibrillation (AF)

In UK Biobank, participants were linked to the National Health Service (NHS) central registers for health-related outcomes (Field IDs: 41270, 41271, 41280 and 41281) and mortality records (Field IDs: 40001 and 40000), and in HUNT2, via linkages to the medical records from the hospitals of the Nord-Trøndelag region and the National Cause of Death Registry.

Hospitalizations or deaths due to AF were identified using ICD-9 code 427.3 and ICD-10 code I48. Incident cases were defined as the first occurrence of either hospitalization or death due to AF during follow-up time. Each participant was followed until either first diagnosis/death due to AF, death due to other cause, loss to follow-up, or end of follow-up (March 23, 2021 for UK Biobank and December 31, 2020 for HUNT2), whichever came first.

Covariates

The following covariates were considered as potential confounders: age, sex, marital status (married, unmarried or separated/divorced/widowed), frequency of alcohol intake (never, monthly, weekly, or daily), smoking history (never, ex-smoker or current smoker), body mass index (BMI), level of physical activity (inactive/low, moderate, or high), Townsend deprivation index (TDI; for UK Biobank only), education attainment (≤10 years, 11-13 years, or ≥14 years), shift work (yes or no), employment status (employed or not employed), systolic blood pressure (SBP), blood cholesterol levels, blood glucose levels, depression (yes or no in UK Biobank; and Hospital Anxiety and Depression Scale (HADS) – Depression scores in HUNT2), anxiety (yes or no in UK Biobank; and HADS – Anxiety scores in HUNT2), use of sleep medication (yes or no) and chronic illness (yes or no). The details on how covariates were handled are described in the supplementary methods.

Statistical analysis

Figure 1 shows the participant selection. Among 441 565 participants in UK Biobank who had information available for sleep traits of interest, a total of 287 352 and 331 748 participants were included in the observational and MR analyses, respectively, after exclusions. Among 52 008 participants in HUNT2, 31 458 and 45 322 were included in the observational and MR analyses,

respectively. Baseline characteristics of the study participants were presented by categories of AF diagnosis for study samples for both UK Biobank and HUNT2 cohorts.

Figure 1: Flow chart of participant selection process

Observational analysis

We used the Cox proportional hazard model to examine the associations of sleep traits on the risk of AF separately in UK Biobank and HUNT2. HRs with 95% CIs were calculated to estimate: (1) the associations of individual sleep traits on the risk of AF and, (2) the joint associations of any two sleep traits together on the risk of AF. The main model was adjusted for age at recruitment, sex, marital status, alcohol intake frequency, smoking status, BMI, physical activity, education, TDI (for UK Biobank only), shift work and employment status. Relative excess risk due to interaction (RERI) was assessed for the joint associations as a test of interaction, when none of the HRs were less than 1 (i.e. preventive).[38,39] RERI equals 0 implies exact additivity (no interaction), RERI > 0 implies more than additivity (positive interaction or synergism), and RERI < 0 implies less than additivity (negative interaction or antagonism).

MR analysis

Genetic risk scores (GRS) were created as instruments for each sleep trait to overcome the weak individual effect of most SNPs on their corresponding sleep trait.[40] Weighted GRS (wGRS) were computed by summing up the participants' sleep trait increasing alleles (morning preference alleles

for chronotype), weighted by the variant effect sizes from the external GWAS. We used wGRS for the main analysis in HUNT2 only, whereas in UK Biobank, we used unweighted GRS (uwGRS) computed simply by summing up the sleep trait increasing alleles. Since all included discovery GWASs used the UK Biobank cohort, the use of internal weights to calculate wGRS is not recommended.[40] Instrument strength was assessed by regression of each sleep trait on their respective GRS and reporting variance explained (R^2) and F-statistics.

MR requires meeting three core assumptions (see supplementary methods).[21,41] We performed one-sample MR analysis to examine the causal effects of individual sleep traits on the risk of AF separately in UK Biobank and HUNT2. A two-stage predictor substitution (TSPS) regression estimator method was used to calculate average causal HRs with 95% CIs. The first stage involved regression of each sleep trait (linear regression for 24-hour sleep duration, and logistic regression for other sleep traits) on their GRS, and the second stage consisted of a Cox regression of AF status on the fitted values from the first stage regression, adjusted for age at recruitment, sex, assessment centre (in UK Biobank), genetic principal components (40 in UK Biobank and 20 in HUNT2), and genotyping chip in both stages. As recommended for MR analysis with a binary outcome, the first stage regression was limited to participants who did not experience AF.[42] The causal estimates for binary exposures (insomnia symptoms, short sleep, long sleep and chronotype) were scaled to represent the risk increase in AF per doubling in the odds of these exposures, by multiplying the obtained β values by 0.693 as previously recommended.[43] The causal estimate for sleep duration indicates the risk increase in AF per additional hour of sleep.

Further, we performed a 2x2 factorial MR analysis to examine the joint causal effects of sleep traits on the risk of AF separately in UK Biobank and HUNT2. Participants were dichotomized across their median GRS (uwGRS for UK Biobank and wGRS for HUNT2) for each sleep trait, with the group equal to or below the median representing low genetic risk for the sleep trait, and the group above the median representing high genetic risk for the sleep trait. Thus, for any combination of two sleep traits, participants were categorized into 4 groups according to their genetic predisposition. For instance, when combining insomnia symptoms and short sleep duration, participants were categorized into: *"Both GRS ≤ median"* (representing low genetic risk for both insomnia symptoms and short sleep duration)‚ *"Insomnia GRS > median"* (representing high genetic risk for insomnia symptoms only), *"Short sleep GRS > median"* (representing high genetic risk for short sleep duration only) and *"Both GRS > median"* (representing high genetic risk for both insomnia symptoms and short sleep duration). We then used Cox regression to estimate the causal HRs with 95% CI, adjusted for age at recruitment, sex, assessment centre (in UK Biobank), genetic principal components (40 in UK Biobank and 20 in HUNT2), and genotyping chip. RERI was assessed for the joint causal effect as a test of interaction, as above.[38,39]

To check the proportional hazards assumption, we used Pearson correlations to test Schoenfeld residuals from both observational Cox regression and MR Cox regression for an association with follow-up time.

Sensitivity analyses
We performed several sensitivity analyses to test the robustness of our findings:
   (1) The observational analysis was repeated for a crude model adjusted for only age at recruitment and sex; and an additional model adjusted for variables including those that could be both confounders and mediators, i.e. SBP, serum cholesterol level, blood glucose level, time since last meal, use of sleep medication(s), depression and anxiety.
   (2) The one-sample MR and 2x2 factorial MR analyses were repeated using uwGRS in HUNT2.
   (3) To assess the second and third MR assumptions that the genetic instruments used are independent of confounders of the exposure-outcome relation and only affect the outcome through the exposure of interest, associations between the GRS and potential confounders were investigated in UK Biobank and HUNT2 to potentially identify any pleiotropic paths. Furthermore, one-sample MR analysis adjusted for any potential confounders found to be

strongly associated with the sleep trait GRS in two cohorts (beyond a Bonferroni significance threshold of $P < 5.88 \times 10^{-4}$ in UK Biobank and $P < 7.81 \times 10^{-4}$ in HUNT2) were explored.

(4) To further investigate potential directional pleiotropy, we derived estimates on SNP-exposure and SNP-outcome associations from the same individuals and applied two-sample MR sensitivity analysis methods: inverse variance weighted (IVW), MR-Egger, weighted median, and weighted mode-based methods. These summary-level methods can be used in a one-sample setting,[44] and the estimates were then compared with the estimates from the individual-level methods. Each of these methods makes different assumptions about the genetic instruments used (see supplementary methods).[45–47]

(5) To further assess consistency in effects estimated for insomnia symptoms, 57 SNPs found robustly associated with insomnia by Lane *et al.*[48] in an older GWAS on UK Biobank (n = 345 022 cases and 108 357 controls) were used in a post hoc one-sample MR Cox regression analysis using same methods as above. These SNPs represent crucial variants for the phenotype any insomnia symptoms ("sometimes"/"usually" as cases versus "never/rarely" as controls).

(6) To evaluate the potential impact of winner's curse, one-sample MR analysis was repeated using genetic variants that replicated at a genome-wide significance level ($P < 5 \times 10^{-8}$) in a large independent dataset for insomnia symptoms (23andMe, n = 944 477, highlighted in supplementary material, Table G1),[35] and chronotype (23andMe, n = 240 098, highlighted in supplementary material, Table G2).[37]

(7) To avoid potential bias due to arbitrary dichotomization and to maximize power, we performed a continuous factorial MR analysis using two GRS (for any combination of two sleep traits) as quantitative traits and their product term.[49] Further, we calculated RERI as a test of interaction using the risk estimates for the quantitative GRS and their product term for each sleep trait combination where none of the HRs were less than 1 (i.e. preventive) for AF.[38,50]

All analyses were conducted using R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria) and performed in line with Strengthening the Reporting of Observational Studies in Epidemiology guidelines for MR studies (STROBE-MR).[51,52]

Results

In the observational analysis, 16 192 out of 287 352 UK Biobank participants had an AF during a mean (standard deviation (SD)) follow-up of 11.6 (2.1) years, and 3 627 out of 31 458 HUNT2 participants had an AF during a mean (SD) follow-up of 20.7 (6.7) years. Participants with an AF during follow-up in the UK Biobank and HUNT2 were more likely to be males, older, have used sleep medication(s), have higher BMI, systolic blood pressure and blood glucose levels, and be suffering from depression and chronic illness. They were less likely to consume alcohol, be physically active, have a tertiary education, work shifts and be employed compared to participants with no diagnosis of AF (Table 1). The HUNT2 participants with an AF were more likely to have higher serum cholesterol levels, but were less likely to be current smokers and suffering from anxiety when compared to participants with no diagnosis of AF, which is contrary to UK Biobank participants with an AF (Table 1). The baseline characteristics were similar among the study participants included in the MR analysis (see supplementary material, Table S2).

Table 1: Baseline characteristics of study participants included in observational analysis with and without an episode of atrial fibrillation (AF) during follow-up in UK Biobank and HUNT2

	UK Biobank (N = 287 352)		HUNT2 (N = 31 458)	
	No AF diagnosis	AF diagnosis	No AF diagnosis	AF diagnosis
Total, % (n)	94.36 (271 160)	5.63 (16 192)	88.47 (27 831)	11.53 (3 627)
Variables, % (n)				
Male	45.55 (123 526)	64.56 (10 454)	45.29 (12 604)	61.54 (2 232)
Married	74.07 (200 856)	73.88 (11 962)	59.81 (16 646)	73.17 (2 654)

Weekly alcohol intake	51.06 (138 465)	46.93 (7 599)	26.53 (7 383)	25.72 (933)
Current smokers	10.22 (27 721)	10.63 (1 722)	29.73 (8 273)	24.21 (878)
Highly physically active	40.61 (110 135)	40.59 (6 572)	38.18 (10 625)	30.30 (1 099)
Tertiary education	46.60 (126 367)	42.37 (6 861)	25.38 (7 063)	18.97 (688)
Shift workers	5.14 (13 936)	3.59 (581)	19.09 (5 313)	9.98 (362)
Employed	60.63 (164 408)	37.96 (6 146)	74.23 (20 660)	51.17 (1 856)
Use of sleep medication(s)	0.87 (2 360)	1.35 (218)	5.45 (1 518)	9.73 (353)
Suffering from depression	11.52 (31 245)	13.94 (2 257)	-	-
Suffering from anxiety	6.13 (16 630)	9.20 (1 489)	-	-
Suffering from chronic illness	29.62 (78 965)	47.63 (7 559)	26.80 (7 342)	45.96 (1 636)
Variables, mean (SD)				
Age, *years*	56.09 (8.04)	61.90 (6.06)	44.34 (14.78)	59.94 (12.68)
TDI	-1.56 (2.92)	-1.41 (3.02)	-	-
BMI, *kg/m^2*	27.17 (4.60)	28.83 (5.25)	25.97 (3.93)	27.52 (4.19)
SBP, *mmHg*	137.40 (18.44)	143.40 (19.24)	133.10 (19.02)	145.90 (21.65)
Serum cholesterol, *mmol/L*	5.74 (1.13)	5.39 (1.18)	5.70 (1.21)	6.18 (1.20)
Blood glucose, *mmol/L*	5.09 (1.16)	5.31 (1.46)	5.30 (1.30)	5.68 (1.62)
HADS - D scores	-	-	3.13 (2.88)	3.83 (3.01)
HADS - A scores	-	-	4.19 (3.26)	4.01 (3.24)

AF, atrial fibrillation; SD, standard deviation; TDI, Townsend deprivation index; BMI, body mass index; SBP, systolic blood pressure; HADS – D scores, Hospital Anxiety and Depression Scale – Depression scores; and HADS – A scores, Hospital Anxiety and Depression Scale – Anxiety scores.

The uwGRS for insomnia symptoms, 24-hour sleep duration, short sleep (≤6 h vs. 7-8 h), long sleep (≥9 h vs. 7-8 h), and morning preference chronotype had F-statistics of 1369.47, 1993.0, 558.61, 270.36, and 5176.33, respectively among UK Biobank participants. The corresponding variance explained (R^2) was 0.41%, 0.60%, 0.18%, 0.11%, and 1.54% (see supplementary material, Table S3). The wGRS for insomnia symptoms, 24-hour sleep duration, short sleep and long sleep had F-statistics of 72.38, 42.63, 5.35, and 4.42, respectively among HUNT2 participants. The corresponding variance explained (R^2) was 0.16%, 0.09%, 0.02%, and 0.01% (see supplementary material, Table S3).

The baseline characteristics were evenly distributed among the factorial groups for any two sleep traits (see supplementary material, Table S4-S10), suggesting that the study participants were randomly assigned to groups of similar sized based on their genetic risk for any two sleep traits.

Individual sleep traits and the risk of AF

Based on the observational analysis, insomnia symptoms were associated with an increased risk of AF in both UK Biobank and HUNT2, with HRs of 1.15 (95% CI 1.06, 1.24) and 1.10 (95% CI 1.00, 1.21), respectively (Figure 2). No association was found for a per hour increase in sleep duration on the risk of AF in UK Biobank and HUNT2, where the corresponding HRs were 0.99 (95% CI 0.96, 1.03) and 0.99 (95% CI 0.96, 1.02). Moreover, short or long sleep duration was not clearly associated with the risk of AF in either cohort. The corresponding HRs in UK Biobank were 1.01 (95% CI 0.93, 1.11) and 1.01 (95% CI 0.88, 1.15), respectively; and in HUNT2 were 0.96 (95% CI 0.53, 1.74) and 1.08 (95% CI 0.99, 1.16), respectively. In addition, morning chronotype was not associated with the risk of AF in UK Biobank (HR 0.95; 95% CI 0.88, 1.02) (Figure 2).

Similar to the observational analysis, there was evidence that per doubling in odds of genetically-determined insomnia symptoms increased the incidence of AF in UK Biobank (HR 1.14; 95% CI 1.07, 1.21), however not in HUNT2 (HR 0.95; 95% CI 0.81, 1.11) (Figure 2). Unlike the observational analysis, each hour increase in genetically-determined sleep duration decreased the incidence of AF in UK Biobank (HR 0.74; 95% CI 0.62, 0.88), but not in HUNT2 (HR 1.06; 95% CI 0.52, 2.15). Further, there was evidence that per doubling in odds of genetically-determined short sleep duration increased the incidence of AF in UK Biobank (HR 1.14; 95% CI 1.04, 1.26), however

the analysis was underpowered in HUNT2 (HR 1.41; 95% CI 0.57, 3.46). Similar to the observational analysis, genetically-determined long sleep duration was not associated with the incidence of AF in UK Biobank (HR 0.92; 95% CI 0.81, 1.05), and the analysis was underpowered in HUNT2 (HR 1.70; 95% CI 0.68, 4.25). Unlike the observational analysis, there was evidence that per doubling in odds of genetically-determined morning preference chronotype was weakly associated with an increased risk of AF in UK Biobank (HR 1.03; 95% CI 0.99, 1.06) (Figure 2).

Figure 2: Observational and one-sample Mendelian randomization Cox regression analysis for incident atrial fibrillation in relation to individual self-reported sleep traits in UK Biobank and HUNT2

Sleep traits	N (incident cases)		Hazard ratio (95% CI)
Insomnia symptoms (Yes vs. No)			
UK Biobank			
Observational analysis	287 352 (16 192)		1.15 (1.06, 1.24)
One-sample MR analysis[†#]	331 748 (19 530)		1.14 (1.07, 1.21)
HUNT2			
Observational analysis	31 458 (3 627)		1.10 (1.00, 1.21)
One-sample MR analysis[‡#]	45 322 (6 296)		0.95 (0.81, 1.11)
24-hour sleep duration (h)			
UK Biobank			
Observational analysis	287 352 (16 192)		0.99 (0.96, 1.03)
One-sample MR analysis[†*]	331 748 (19 530)		0.74 (0.62, 0.88)
HUNT2			
Observational analysis	31 458 (3 627)		0.99 (0.96, 1.02)
One-sample MR analysis[‡*]	45 322 (6 296)		1.06 (0.52, 2.15)
Short sleep (≤6 h vs. 7-8 h)			
UK Biobank			
Observational analysis	265 945 (14 533)		1.01 (0.93, 1.11)
One-sample MR analysis[†#]	306 292 (17 498)		1.14 (1.04, 1.26)
HUNT2			
Observational analysis	23 932 (2 487)		0.96 (0.53, 1.74)
One-sample MR analysis[‡#]	33 588 (4 198)		1.41 (0.57, 3.46)
Long sleep (≥9 h vs. 7-8 h)			
UK Biobank			
Observational analysis	220 385 (12 334)		1.01 (0.88, 1.15)
One-sample MR analysis[†#]	253 111 (14 738)		0.92 (0.81, 1.05)
HUNT2			
Observational analysis	29 514 (3 428)		1.08 (0.99, 1.16)
One-sample MR analysis[‡#]	42 506 (5 932)		1.70 (0.68, 4.25)
Chronotype (Morning vs. Evening)			
UK Biobank			
Observational analysis	287 352 (16 192)		0.95 (0.88, 1.02)
One-sample MR analysis[†#]	331 748 (19 530)		1.03 (0.99, 1.06)

0.5   1   2   3   4   5
Hazard ratio
(95% CI)

CI, confidence interval; MR, Mendelian randomization.
Observational analysis represents main model adjusted for age, sex, marital status, alcohol intake frequency, smoking status, body mass index, physical activity, education, Townsend deprivation index (for UK Biobank only), shift work and employment status.
Chronotype was missing in HUNT2.

Combination of sleep traits and the risk of AF

Insomnia symptoms with short sleep duration
Based on the observational analysis, for UK Biobank participants who reported short sleep duration without insomnia symptoms, there was little evidence of a decreased risk of AF (HR 0.98; 95% CI 0.86, 1.11), while for those who reported short sleep duration with insomnia symptoms, there was weak evidence of an increased risk (HR 1.10; 95% CI 0.98, 1.25), and for those who reported normal sleep duration with insomnia symptoms, there was strong evidence of an increased risk of AF (HR 1.14; 95% CI 1.03, 1.26) when compared to those who reported normal sleep duration without insomnia symptoms (Figure 3). There was a similar pattern in HUNT2, however the corresponding HRs were imprecise (Figure 3).

In UK Biobank, participants with only a high genetic risk for insomnia symptoms or high genetic risk for short sleep duration had a slightly higher risk of AF (HR 1.03; 95% CI 0.99, 1.07 and HR 1.02; 95% CI 0.97, 1.06, respectively), whereas participants with high genetic risks for both traits had the highest risk (HR 1.08; 95% CI 1.03, 1.12) (Figure 3); however, there was no evidence of interaction (RERI 0.03; 95% CI -0.03, 0.09). This pattern was not consistent in HUNT2, showing imprecise estimates (Figure 3).

Figure 3: Observational and 2x2 factorial Mendelian randomization Cox regression analysis assessing the joint effects of insomnia symptoms and sleep duration on the risk of atrial fibrillation in UK Biobank and HUNT2

	Observational analysis[†]			Factorial MR analysis[‡]		
	N (incident cases)		Hazard ratio (95% CI)	N (incident cases)		Hazard ratio (95% CI)[*]
Insomnia symptoms - Short sleep						
UK Biobank						
No - No	158 104 (8 113)		1 [Reference]	Both GRS ≤ median	81 693 (4 533)	1 [Reference]
Yes - No	40 874 (2 562)		1.14 (1.03, 1.26)	Insomnia GRS > median	71 453 (4 038)	1.03 (0.99, 1.07)
No - Yes	33 116 (1 748)		0.98 (0.86, 1.11)	Short sleep GRS > median	71 453 (4 064)	1.02 (0.97, 1.06)
Yes - Yes	33 851 (2 110)		1.10 (0.98, 1.25)	Both GRS > median	81 693 (4 863)	1.08 (1.03, 1.12)
HUNT2						
No - No	19 547 (1 927)		1 [Reference]	Both GRS ≤ median	9 015 (1 185)	1 [Reference]
Yes - No	2 441 (361)		1.23 (0.73, 2.08)	Insomnia GRS > median	7 779 (929)	0.95 (0.87, 1.04)
No - Yes	1 526 (139)		0.96 (0.48, 1.92)	Short sleep GRS > median	7 779 (976)	0.98 (0.90, 1.06)
Yes - Yes	418 (60)		1.09 (0.34, 3.51)	Both GRS > median	9 015 (1 108)	0.96 (0.89, 1.04)
Insomnia symptoms - Long sleep						
UK Biobank						
No - No	158 104 (8 113)		1 [Reference]	Both GRS ≤ median	73 153 (4 215)	1 [Reference]
Yes - No	40 874 (2 562)		1.11 (1.00, 1.24)	Insomnia GRS > median	74 794 (4 478)	1.05 (1.01, 1.10)
No - Yes	16 894 (1 224)		0.96 (0.82, 1.11)	Long sleep GRS > median	53 403 (2 995)	0.98 (0.94, 1.03)
Yes - Yes	4 513 (435)		1.36 (1.04, 1.79)	Both GRS > median	51 761 (3 050)	1.03 (0.99, 1.08)
HUNT2						
No - No	19 547 (1 927)		1 [Reference]	Both GRS ≤ median	10 378 (1 450)	1 [Reference]
Yes - No	2 441 (361)		1.11 (0.98, 1.24)	Insomnia GRS > median	10 875 (1 481)	0.98 (0.91, 1.06)
No - Yes	6 430 (941)		1.09 (1.00, 1.19)	Long sleep GRS > median	10 875 (1 568)	1.00 (0.93, 1.08)
Yes - Yes	1 096 (199)		1.12 (0.96, 1.31)	Both GRS > median	10 378 (1 433)	1.02 (0.94, 1.09)

CI, confidence interval; MR, Mendelian randomization.

In the observational analysis for each sleep trait combination, "No – No" represents absence of both sleep traits in combination, "Yes – No" represents presence of first sleep trait and absence of second, "No – Yes" represents absence of first sleep trait and presence of second, and "Yes – Yes" represents presence of both sleep traits.

In the factorial MR analysis for each sleep trait combination, both GRS ≤ median represents low genetic risk for both sleep traits in combination, sleep trait 1 GRS > median represents high genetic risk for sleep trait 1 only, sleep trait 2 GRS > median represents high genetic risk for sleep trait 2 only and both GRS > median represents high genetic risk for both sleep traits.

[†] Estimates from main model, adjusted for age, sex, marital status, alcohol intake frequency, smoking status, body mass index, physical activity, education, Townsend deprivation index (for UK Biobank only), shift work, and employment status.

[‡] Estimates adjusted for age, sex, assessment centre (in UK Biobank), genetic principal components (40 in UK Biobank and 20 in HUNT2), and genotyping chip.

[*] Derived using unweighted genetic risk score for each sleep trait in UK Biobank, whereas using weighted genetic risk score for each sleep trait in HUNT2.

Insomnia symptoms with long sleep duration
Based on the observational analysis, for UK Biobank participants who reported long sleep duration without insomnia symptoms, there was little evidence of a decreased risk of AF (HR 0.96; 95% CI 0.82, 1.11), while for those who reported long sleep duration with insomnia symptoms, there was strong evidence of an increased risk (HR 1.36; 95% CI 1.04, 1.79) and for those who reported normal sleep duration with insomnia symptoms, there was slightly weaker evidence of an increased risk of

AF (HR 1.11; 95% CI 1.00, 1.24) when compared to those who reported normal sleep duration without insomnia symptoms (Figure 3). However, the joint association of insomnia symptoms and long sleep duration on the risk of AF was inconclusive in HUNT2 (Figure 3).

The factorial MR analysis of genetic risks for insomnia symptoms and long sleep duration on risk of AF, was inconclusive in both UK Biobank and HUNT2 (Figure 3).

Figure 4: Observational and 2x2 factorial Mendelian randomization Cox regression analysis assessing the joint effects of insomnia symptoms/sleep duration and chronotype on the risk of incident atrial fibrillation in UK Biobank

	Observational analysis[†]			Factorial MR analysis[‡]		
	N (incident cases)		Hazard ratio (95% CI)		N (incident cases)	Hazard ratio (95% CI)*
Insomnia symptoms - Chronotype[#]						
No - No	77 439 (3 910)		1 [Reference]	Both GRS ≤ median	80 092 (4 545)	1 [Reference]
Yes - No	29 507 (1 835)		1.18 (1.04, 1.35)	Insomnia GRS > median	85 782 (5 076)	1.06 (1.02, 1.10)
No - Yes	130 675 (7 175)		0.96 (0.88, 1.05)	Chronotype GRS > median	85 782 (5 034)	1.04 (0.99, 1.08)
Yes - Yes	49 731 (3 272)		1.08 (0.97, 1.21)	Both GRS > median	80 092 (4 875)	1.08 (1.04, 1.13)
Short sleep - Chronotype[#]						
No - No	73 714 (3 761)		1 [Reference]	Both GRS ≤ median	77 263 (4 313)	1 [Reference]
Yes - No	24 173 (1 285)		1.04 (0.89, 1.22)	Short sleep GRS > median	75 883 (4 306)	1.01 (0.96, 1.05)
No - Yes	125 264 (6 914)		0.96 (0.87, 1.05)	Chronotype GRS > median	75 883 (4 258)	1.00 (0.96, 1.04)
Yes - Yes	42 794 (2 573)		0.96 (0.85, 1.09)	Both GRS > median	77 263 (4 621)	1.06 (1.02, 1.10)
Long sleep - Chronotype[#]						
No - No	73 714 (3 761)		1 [Reference]	Both GRS ≤ median	71 916 (4 209)	1 [Reference]
Yes - No	9 059 (699)		1.11 (0.90, 1.37)	Long sleep GRS > median	54 640 (3 122)	0.98 (0.94, 1.03)
No - Yes	125 264 (6 914)		0.99 (0.90, 1.09)	Chronotype GRS > median	76 031 (4 484)	1.01 (0.97, 1.05)
Yes - Yes	12 348 (960)		0.93 (0.77, 1.11)	Both GRS > median	50 524 (2 923)	0.99 (0.95, 1.04)

0.8 1 1.2 1.4
Hazard ratio (95% CI)

0.9 1 1.1 1.2
Hazard ratio (95% CI)

CI, confidence interval; MR, Mendelian randomization.

In the observational analysis for each sleep trait combination, "No – No" represents absence of both sleep traits in combination, "Yes – No" represents presence of first sleep trait and absence of second, "No – Yes" represents absence of first sleep trait and presence of second, and "Yes – Yes" represents presence of both sleep traits.

In the factorial MR analysis for each sleep trait combination, both GRS ≤ median represents low genetic risk for both sleep traits in combination, sleep trait 1 GRS > median represents high genetic risk for sleep trait 1 only, sleep trait 2 GRS > median represents high genetic risk for sleep trait 2 only and both GRS > median represents high genetic risk for both sleep traits.

[†] Estimates from main model, adjusted for age, sex, marital status, alcohol intake frequency, smoking status, body mass index, physical activity, education, Townsend deprivation index, shift work, and employment status.

[‡] Estimates adjusted for age, sex, assessment centre, 40 genetic principal components, and genotyping chip.

* Derived using unweighted genetic risk score for each sleep trait in UK Biobank.

[#] Chronotype - morning vs. evening preference; or chronotype genetic risk score calculated using alleles for morning preference.

Chronotype with insomnia symptoms or short/long sleep duration

Based on the observational analysis, for UK Biobank participants who reported morning chronotype without insomnia symptoms, there was little evidence of a decreased risk of AF (HR 0.96; 95% CI 0.88, 1.05), while for those who reported morning chronotype with insomnia symptoms, there was weak evidence of an increased risk (HR 1.08; 95% CI 0.97, 1.21) and for those who reported evening chronotype with insomnia symptoms, there was strong evidence of an increased risk of AF (HR 1.18; 95% CI 1.04, 1.35) when compared to those who reported evening chronotype without insomnia symptoms (Figure 4). However, the joint associations of morning chronotype and short sleep duration, as well as morning chronotype and long sleep duration on the risk of AF were inconclusive in UK Biobank (Figure 4).

In addition, UK Biobank participants with only a high genetic risk for insomnia symptoms or high genetic risk for a morning chronotype had a slightly higher risk of AF (HR 1.06; 95% CI 1.02, 1.10 and HR 1.04; 95% CI 0.99, 1.08, respectively), whereas participants with high genetic risk for both sleep traits had the highest risk (HR 1.08; 95% CI 1.04, 1.13) (Figure 4); however, there was no evidence of interaction (RERI -0.01; 95% CI -0.07, 0.04). The UK Biobank participants with only a high genetic risk for short sleep duration or high genetic risk for a morning chronotype had no increased risk of AF (HR 1.01; 95% CI 0.96, 1.05 and HR 1.00; 95% CI 0.96, 1.04, respectively), whereas participants with high genetic risk for both sleep traits had an increased risk (HR 1.06; 95% CI 1.02, 1.10), although again there was no statistical evidence of interaction (RERI 0.06; 95% CI -

0.01, 0.12). The factorial MR analysis of genetic risks for long sleep duration and morning chronotype on risk of AF in UK Biobank was inconclusive (Figure 4).

The proportionality of hazards assumption was held for all the observational and MR Cox regression analyses (see supplementary material, Tables S11-S12).

Sensitivity analysis

(1) Further adjustment of potential confounding variables did not change the results markedly when repeating the observational analysis with additional potential confounders (see supplementary material, Tables S13-S19).

(2) Using the uwGRS for the sleep traits in HUNT2, the one-sample MR estimates changed markedly for short sleep duration (HR 1.97; 95% CI 0.68, 5.72 versus HR 1.41; 95% CI 0.57, 3.46 for wGRS) and long sleep duration (HR 1.19; 95% CI 0.64, 2.23 versus HR 1.70; 95% CI 0.68, 4.25 for wGRS), but only slightly for insomnia symptoms and 24-hour sleep duration (see supplementary material, Table S20). However, the 2x2 factorial MR estimates remained unchanged (see supplementary material, Figure S1).

(3) Even after correction for multiple testing, several confounding factors were associated with the sleep trait GRS in both UK Biobank and HUNT2 which might indicate potential pleiotropy (see supplementary material, Tables S21 & S22). Further sensitivity analysis was undertaken adjusting for these potential confounders in the one-sample MR analysis, and the effect estimates for insomnia symptoms (HR 1.05; 95% CI 0.97, 1.13) and short sleep duration (HR 1.09; 95% CI 0.98, 1.22) attenuated slightly and were less precise. Moreover, adjusting for potential confounders, the effect estimate for 24-hour sleep duration attenuated slightly in UK Biobank (HR 0.82; 95% CI 0.67, 1.00) (see supplementary material, Table S23).

(4) The causal estimates obtained using MR-Egger, weighted median- and weighted mode-based methods attenuated slightly and were less precise (see supplementary material, Figures S2-S6, Tables S24 & S25).

(5) Further, the post hoc one-sample MR analysis using insomnia symptoms variants from Lane *et al.*[48] gave similar results, where the TSPS estimates from UK Biobank and HUNT2 showed a suggestive adverse causal effect (HR 1.08; 95% CI 0.99, 1.18 and HR 1.11; 95% CI 0.87, 1.41, respectively) (see supplementary material, Figure S7 and Table S26).

(6) The causal estimates attenuated only slightly when using the GRS consisting of 116 insomnia SNPs (one missing in the HUNT imputed dataset) and 72 chronotype SNPs which replicated at a genome-wide significance level ($P < 5x10^{-8}$) in the independent 23andMe dataset (see supplementary material, Tables S27 & S28).

(7) The estimates from the continuous factorial MR analysis using sleep trait GRS as quantitative traits (per standard deviation increase) and their product term inferred similar effects (see supplementary material, Figure S8). In UK Biobank, the GRS for insomnia symptoms and short sleep duration were associated with an increased risk of AF (HR 1.03; 95% CI 1.01, 1.04 and HR 1.02; 95% CI 1.00, 1.03, respectively), but there was no evidence of interaction (RERI 0.01; 95% CI -0.01, 0.02). Similarly, the GRS for insomnia symptoms and morning chronotype were associated with an increased risk of AF (HR 1.03; 95% CI 1.02, 1.05 and HR 1.01; 95% CI 1.00, 1.03, respectively), though there was no evidence of interaction (RERI -0.01; 95% CI -0.02, 0.01). Also, the GRS for short sleep duration and morning chronotype were associated with an increased risk of AF (HR 1.02; 95% CI 1.00, 1.04 and HR 1.01; 95% CI 1.00, 1.03, respectively), with no evidence of interaction (RERI 0.01; 95% CI -0.01, 0.02).

The STROBE-MR checklist was presented in the supplementary material (Table S29).

Discussion

In the observational analysis, we found insomnia symptoms were associated with an increased risk of AF, whereas there was limited evidence of association for sleep duration (including short or long sleep) and chronotype in both cohorts. In the one-sample MR analysis, we found evidence of adverse effects of insomnia symptoms and short sleep duration, and a protective effect of sleep duration on the risk of AF in UK Biobank. However, these associations were either not supported or too imprecise in HUNT2 for validation, likely due to low power in this cohort.

There was no evidence of relative excess risk due to interaction, suggesting the joint effect of two sleep traits on AF does not exceed the effect of each sleep trait assessed independently. Although in the factorial MR analysis participants with high genetic risks for two sleep traits in certain combinations (i.e., insomnia symptoms with short sleep duration, insomnia symptoms with morning chronotype, and short sleep duration with morning chronotype) had higher risks of AF than those with high genetic risk for a single sleep trait, but in UK Biobank only. These results were not replicated in HUNT2, where the estimates were imprecise.

Comparison of observational and MR findings across other studies

Our findings of an adverse effect of insomnia symptoms on risk of AF in all analyses performed in UK Biobank are consistent across much of the previous observational[10,53] and MR studies.[23–25,54] However, in HUNT2, our observational analysis found weak evidence of an increased risk of AF, whereas our one-sample MR analysis showed no effect of insomnia symptoms on the risk of AF. A recent observational study conducted using the third survey of the Trøndelag Health Study (HUNT3; n = 33 983) found no association between insomnia symptoms and the risk of AF.[55] This lack of replication in HUNT2 and HUNT3 could be due to low statistical power from its smaller sample, where larger study sizes might have shown some associations. Moreover, the estimated effect of insomnia symptoms using fewer SNPs from Lane *et al.*[48] showed the tendency towards an increased risk of AF in participants genetically predisposed to insomnia symptoms (HR 1.11; 95% CI 0.87, 1.41) in HUNT2.

Our findings of no association of 24-hour sleep duration on the risk of AF from observational analysis in both cohorts could be due to underlying U-shaped association, as evident from previous observational studies noting that both short and long sleep durations increase the risk of AF.[11,53,56–58] However, surprisingly, we found no associations of short (≤6 h vs. 7-8 h) or long (≥9 h vs. 7-8 h) sleep durations when assessed separately in the observational analysis. On the other hand, one-sample MR findings in UK Biobank suggested a protective effect per hour increase in sleep duration and an adverse effect of short sleep duration on the risk of AF, which are in line with previous MR analyses.[26,27] However, these findings were not replicated in HUNT2, which again may be due to smaller sample and/or weak instrument for short sleep duration.

Our observational findings of no association of chronotype on the risk of AF in the UK Biobank align with prior research.[53] Also, our MR findings indicate no causal effect of chronotype on the risk of AF in UK Biobank.

Overall, there was no statistical evidence of interaction among different combinations of sleep traits, suggesting the joint effect of sleep traits on AF does not exceed the effect of each sleep trait assessed independently (i.e., no evidence of synergism). Although a prior observational study in UK Biobank found healthy sleep patterns (represented by morning chronotype, adequate sleep duration (7–8 h), no frequent insomnia symptoms, no snoring, and no frequent daytime sleepiness) were associated with a lower risk of AF.[53] Interestingly, in our factorial MR analysis participants with high genetic risks for two sleep traits in certain combinations (i.e., insomnia symptoms with short sleep duration, insomnia symptoms with morning chronotype, and short sleep duration with morning chronotype) had higher risks of AF than those with high genetic risk for a single sleep trait in UK Biobank. However, this was

not replicated in HUNT2, possibly due to low power from a smaller sample and/or weak instruments for short and long sleep durations.

Potential mechanisms

The definitive mechanisms mediating detrimental effects of sleep disturbances on AF risk remain elusive. Nonetheless, it is postulated that insomnia symptoms and short sleep duration trigger a range of physiological processes, including autonomic dysregulation,[59–61] activation of proinflammatory and oxidative stress pathways,[62] dysregulation of hypothalamic-pituitary axis,[63] and activation of renin-aldosterone-angiotensin system.[64] These processes may contribute to atrial remodelling and fibrosis,[65–67] resulting in the loss of atrial muscle mass and subsequent promotion of proarrhythmic conditions conducive to AF incidence. Given there was no evidence of relative excess risk due to interaction, we do not suspect these potential mechanisms to interplay with each other.

Strengths and limitations

Our study is the first to explore the role of individual sleep traits and their joint effects on the incidence of AF using multiple approaches in two large cohorts – the UK Biobank and the HUNT study. Incidence of AF was ascertained using linkage of the cohorts to hospital records and death certificates which reduced bias due to misclassification. Furthermore, this study benefitted from the MR analyses that use SNPs from three large GWASs for insomnia symptoms,[35] sleep duration[36] and chronotype.[37]

The present study employs various approaches that exhibit distinct advantages and disadvantages. In observational analyses, efforts were made to alleviate possible sources of bias, such as confounding and reverse causation, by utilizing multivariable Cox regression of incident AF and controlling for several potential confounders. However, to further minimize the likelihood of bias due to confounding, reverse causation and measurement error, we applied MR.

However, our study has several limitations. Self-reported measures of sleep traits were used in observational analyses, as well as to identify genetic variants for subsequent MR analysis. It remains unclear if self-reported sleep duration captures time in bed or actual sleep time. The insomnia questions used in both cohorts did not cover all components used in the framework for diagnosing insomnia.[31] Our use of a simplified definition of insomnia considers people with some-to-severe insomnia in this study, which may underestimate our findings where previous studies indicate that the consequences of insomnia are related to insomnia severity.[68,69] Chronotype was assessed from a single question about chronotype in UK Biobank, rather than considering validated tools.[70,71] Also, the biological functions of the genetic variants employed in MR analysis to predict sleep traits, and the mechanistic pathways underlying their observed effects remain poorly understood.

We used sleep traits as binary exposures (except 24-hour sleep duration), which are likely coarsened approximations of the true latent exposure.[72] This deliberate loss of information may increase the likelihood of false positive findings, but also opens up alternate pathways from the genetic instruments to the outcome, which may violate the exclusion restriction assumption of MR and result in biased effect estimates.[72] Our investigations may have been impelled to identify any non-linear effects of the exposures due to their binary nature. However, we also acknowledge that application of non-linear MR methods is underdevelopment.[73,74]

The selection of participants may be a source of bias and may limit generalizability. We relied on our findings from UK Biobank due to its large sample, although it is not representative of the UK population owing to low participation (5.5% response rate),[75] and may have led to bias in both the observational and MR estimates of association through selection bias.[76–79] On the other hand, HUNT2 (69.5% response rate) is more representative of the general population and may be subject to less bias, which could explain why the estimates for the UK Biobank and HUNT2 differed. Moreover, the study sample restricting to participants from European ancestry in both cohorts may further limit generalizability of our findings to other ethnicities.

The limited sample size of the HUNT2 study may have resulted in inadequate statistical power, leading to the potential oversight of weak evidence of an effect. Moreover, the genetic instruments employed explained much less variance in the sleep traits, particularly for short and long sleep durations within the HUNT2 sample, raising concerns about weak instrument bias.[80] A simulation study has shown that use of bootstrapping to obtain corrected standard errors is limited to the availability of strong instruments.[81] Thus, we restricted the use of bootstrapping in our MR analyses owing to weak instruments for short and long sleep durations in HUNT2. Furthermore, the SNPs used to construct the GRS for short and long sleep durations were not assessed for replication in other independent cohorts,[36] implying that the validity of the GRS for short and long sleep durations utilized in this study is not established in any other population.

Despite our considerable efforts to limit potential confounding in the observational analysis, we recognize that residual confounding due to measurement errors or misclassification of the confounders, as well as confounding due to factors not considered/collected still persists.[82] An important example of such factor is obstructive sleep apnoea (OSA), which is a well-established risk factor for AF.[83] We did not have information on OSA or other sleep disorders in our study. OSA changes intrathoracic pressure, leading to cyclic augmentation of atrial wall stress. This stress can further exacerbate autonomic dysregulation and inflammation pathways,[84] which are potentially pathophysiological in the development of AF. For OSA to be able to substantially influence our estimates, it must be unrelated to other covariates controlled for in the models, while also being strongly associated with both the exposure and the outcome. OSA is known to be correlated with age, BMI, blood pressure and depression.[85,86] By adjusting for these related variables in our observational analysis, we have partially accounted for some of the confounding that could arise from OSA. Thus, it seems unlikely that OSA alone could explain increased risk of AF observed among participants with insomnia symptoms and short sleep duration. Moreover, OSA is both underdiagnosed and under-recognized.[87]

In all MR analysis, we could not exclude the possibility of pleiotropy.[88] However, we applied several robust methods (such as MR-Egger, weighted median and weighted mode based methods) as sensitivity analyses to test for horizontal pleiotropy.[44] Although these methods produce less precise estimates, consistent results in the same direction strengthens confidence in identification of causal links. We also found that genetic risk for insomnia symptoms was strongly associated with BMI, smoking status, depression, and education among other covariates, which may be indicative of confounding, mediation or horizontal pleiotropy.[35] However, our results remained fairly consistent across various MR robust methods. Additionally, previous studies have showed only mild attenuation of causal effects of insomnia symptoms on AF risk when adjusted for BMI, smoking, depression and education using multivariable Mendelian randomization.[23,24]

The SNP-exposure estimates were obtained from three GWASs on sleep traits, where UK Biobank formed part of the discovery cohort. This could lead to winner's curse, when the magnitude of the effect sizes for genetic variants identified within a discovery cohort is likely to be exaggerated.[89] In a one-sample MR analysis, the impact of winner's curse of the SNP-exposure association can bias estimates towards the confounded observational estimate.[89] We therefore used unweighted GRS for our sleep traits in UK Biobank to minimize any bias of winner's curse.[40] To further check the impact of winner's curse in one-sample MR, we derived GRS for insomnia symptoms and chronotype composed of SNPs that replicated in an independent sample (i.e., 23andMe).[35,37] However, we could not apply the same approach to check the impact of winner's curse on sleep duration due to the limited sample size of the replication dataset, meaning that genetic associations might be imprecise.[36] Moreover, we acknowledge availability of information from latest GWAS meta-analysis of insomnia conducted on 593 724 cases and 1 771 286 controls, including data from the UK Biobank and 23andMe.[90] This analysis identified 554 risk loci, with 364 being novel for insomnia. Nonetheless, our study relied on individual-level genetic data to compute the GRS of insomnia, where SNP information was limited.

Although factorial MR is a promising approach for investigating the joint effects of multiple exposures on a particular outcome, one of the main concern is the underpowered nature of this approach, which can lead to false negative results.[49] Nevertheless, this study addressed this limitation by utilizing the UK Biobank cohort, consisting of 331 748 participants, representing the largest factorial MR study conducted to date on sleep traits. Moreover, the good instrument strength observed in UK Biobank cohort further mitigate concerns due to underpowered factorial MR findings.[91] However, this may also be a limitation due to sample overlap with the discovery cohort. Additionally, it is important to acknowledge that MR assumes that the exposures remain stable throughout an individual's life course,[22] and as such, any observed joint effects should be interpreted with caution. While factorial MR can effectively identify if two independent exposures interact and have a joint effect that holds public health significance,[91] it is critical to consider the potential variations in exposure over time and how these fluctuations might affect the magnitude of observed effects.

Furthermore, direct comparison of the findings from observational and MR study designs must be done cautiously, as disparities in results may stem from methodological differences. MR estimates the effect of small differences in lifelong exposures, which might not be directly comparable to the effects of self-reported exposure differences over limited periods in conventional observational study designs. Also, it is crucial to acknowledge that potential interaction effects could be apparent only at certain thresholds. In our study, the use of sleep traits as binary exposures, we overlook whether the differences in sleep traits among groups in the 2x2 factorial analysis (dichotomized across median GRS cut-offs) correspond to an important distinction in exposures or if the differences between groups are too small to detect interaction effects.

Conclusions

This study reveals that individuals with two sleep traits do not have a risk of AF that exceeds the additive risk from the individual sleep traits (i.e., no relative excess risk due to interaction), indicating the effect of each sleep traits on AF are likely to be independent of each other. Using both observational and MR study design this study also provides strong evidence for an adverse causal effect of insomnia symptoms on the incidence of AF. There is some evidence of an adverse causal effect of short sleep duration and a protective causal effect of an additional hour of sleep duration on the incidence of AF. Our findings support effective management of insomnia symptoms and short sleep duration in general population to mitigate the risk of AF and improve overall cardiovascular health.

Acknowledgements

This research has been conducted using data from UK Biobank, a major biomedical database (https://www.ukbiobank.ac.uk/), under application number 40135.

The Trøndelag Health Study (HUNT) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU)), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. We want to thank clinicians and other employees at Nord-Trøndelag Hospital Trust for their support and for contributing to data collection in this research project.

Funding statement

This study was made possible with the financial support from the Norwegian Health Association (*Norwegian*: Nasjonalforeningen for folkehelsen; project number 19479), mobility grant funds from the Liaison Committee for Education, Research and Innovation in Central Norway (*Norwegian*: Samarbeidsorganet mellom NTNU og Helse Midt-Norge; project number 2023/34249) and top-up financing from the Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Laxmi Bhatta received support from the Liaison Committee for Education, Research and Innovation in Central Norway (*Norwegian*: Samarbeidsorganet mellom NTNU og Helse Midt-Norge); and the Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU.

Disclosure of interest

The authors declare that there is no conflict of interest. The authors of this manuscript have certified that they comply with the principles of ethical publishing.

Data availability statement

The data supporting the findings are available in the supplementary material and upon request. The UK Biobank data is available to researchers, subject to successful registration and application process via their website (https://www.ukbiobank.ac.uk/). The data from the HUNT Study are available from the HUNT Research Centre but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. However, the data are available for export given approval of application to the HUNT Research Centre (http://www.ntnu.edu/hunt/data). The data on hospital records linkages to the HUNT Study participants are available from Nord-Trøndelag Hospital Trust and require permission. All other data used are publicly available and referenced according in the main text.

Ethical approval and consent

UK Biobank received ethical approval from the National Health Service (NHS) Research Ethics Service (reference number 11/NW/0382). The HUNT Study was approved by the Data Inspectorate of Norway and recommended by the Regional Committee for Ethics in Medical Research (REK; reference number 152/95/AH/JGE). The ethical approval for conducting this study was also obtained from the Regional Committee for Ethics in Medical Research (REK nord; reference number 2020/47206).

Informed consent was obtained from all individual participants of both the cohorts included in this study.

CRediT statement

Conceptualization: BMB, RCR, ESS, LBS, BOÅ; Data curation: NA, JPL, VM, RCR, LBS; Formal analysis: NA; Funding acquisition: NA, LBS; Methodology: NA, BMB, LB, RCR, LBS; Project

References

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. *Journal of the American College of Cardiology* 2020;**76**:2982–3021.

2. Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century. *Circulation Research* American Heart Association; 2020;**127**:4–20.

3. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. *International Journal of Stroke* SAGE Publications; 2021;**16**:217–221.

4. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. *Circ Res* 2017;**120**:1501–1517.

5. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of Atrial Fibrillation on Mortality, Stroke, and Medical Costs. *Archives of Internal Medicine* 1998;**158**:229–234.

6. Tobaldini E, Fiorelli EM, Solbiati M, Costantino G, Nobili L, Montano N. Short sleep duration and cardiometabolic risk: from pathophysiology to clinical evidence. *Nat Rev Cardiol* Nature Publishing Group; 2019;**16**:213–224.

7. McAlpine CS, Kiss MG, Rattik S, He S, Vassalli A, Valet C, et al. Sleep modulates haematopoiesis and protects against atherosclerosis. *Nature* Nature Publishing Group; 2019;**566**:383–387.

8. Ozer O, Ozbala B, Sari I, Davutoglu V, Maden E, Baltaci Y, et al. Acute Sleep Deprivation is Associated with Increased QT Dispersion in Healthy Young Adults. *Pacing and Clinical Electrophysiology* 2008;**31**:979–984.

9. Esen Ö, Akçakoyun M, Açar G, Bulut M, Ali□zade E, Kargin R, et al. Acute Sleep Deprivation Is Associated with Increased Atrial Electromechanical Delay in Healthy Young Adults. *Pacing and Clinical Electrophysiology* 2011;**34**:1645–1651.

10. Lee H-H, Chen Y-C, Chen J-J, Lo S-H, Guo Y-L, Hu H-Y. Insomnia and the Risk of Atrial Fibrillation: A Population-Based Cohort Study. *Acta Cardiol Sin* 2017;**33**:165–172.

11. Arafa A, Kokubo Y, Shimamoto K, Kashima R, Watanabe E, Sakai Y, et al. Sleep duration and atrial fibrillation risk in the context of predictive, preventive, and personalized medicine: the Suita Study and meta-analysis of prospective cohort studies. *EPMA J* 2022;**13**:77–86.

12. Arora N, Richmond RC, Brumpton BM, Åsvold BO, Dalen H, Skarpsno ES, et al. Self-reported insomnia symptoms, sleep duration, chronotype and the risk of acute myocardial infarction (AMI): a prospective study in the UK Biobank and the HUNT Study. *Eur J Epidemiol* 2023;

13. Fan Y, Wu Y, Peng Y, Zhao B, Yang J, Bai L, et al. Sleeping Late Increases the Risk of Myocardial Infarction in the Middle-Aged and Older Populations. *Frontiers in Cardiovascular Medicine* 2021;**8**.

14. Buysse DJ. Sleep Health: Can We Define It? Does It Matter? *Sleep* 2014;**37**:9–17.

15. Bertisch SM, Pollock BD, Mittleman MA, Buysse DJ, Bazzano LA, Gottlieb DJ, et al. Insomnia with objective short sleep duration and risk of incident cardiovascular disease and all-cause mortality: Sleep Heart Health Study. *Sleep* 2018;**41**.

16. Kalmbach DA, Pillai V, Arnedt JT, Drake CL. DSM-5 Insomnia and Short Sleep: Comorbidity Landscape and Racial Disparities. *Sleep* 2016;**39**:2101–2111.

17. Sands-Lincoln M, Loucks EB, Lu B, Carskadon MA, Sharkey K, Stefanick ML, et al. Sleep Duration, Insomnia, and Coronary Heart Disease Among Postmenopausal Women in the Women's Health Initiative. *J Womens Health (Larchmt)* 2013;**22**:477–486.

18. Vgontzas AN, Fernandez-Mendoza J, Liao D, Bixler EO. Insomnia with objective short sleep duration: The most biologically severe phenotype of the disorder. *Sleep Medicine Reviews* 2013;**17**:241–254.

19. Fernandez-Mendoza J, Vgontzas AN, Liao D, Shaffer ML, Vela-Bueno A, Basta M, et al. Insomnia With Objective Short Sleep Duration and Incident Hypertension. *Hypertension* American Heart Association; 2012;**60**:929–935.

20. Fernandez-Mendoza J. The insomnia with short sleep duration phenotype: an update on it's importance for health and prevention. *Current Opinion in Psychiatry* 2017;**30**:56.

21. Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* British Medical Journal Publishing Group; 2018;**362**:k601.

22. Burgess S, Thompson SG. Mendelian Randomization: Methods for Causal Inference Using Genetic Variants. 2nd ed. New York: Chapman and Hall/CRC; 2021.

23. Larsson SC, Markus HS. Genetic Liability to Insomnia and Cardiovascular Disease Risk. *Circulation* American Heart Association; 2019;**140**:796–798.

24. Yuan S, Mason AM, Burgess S, Larsson SC. Genetic liability to insomnia in relation to cardiovascular diseases: a Mendelian randomisation study. *Eur J Epidemiol* 2021;**36**:393–400.

25. Liu X, Li C, Sun X, Yu Y, Si S, Hou L, et al. Genetically Predicted Insomnia in Relation to 14 Cardiovascular Conditions and 17 Cardiometabolic Risk Factors: A Mendelian Randomization Study. *J Am Heart Assoc* 2021;**10**:e020187.

26. Ai S, Zhang J, Zhao G, Wang N, Li G, So H-C, et al. Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank. *European Heart Journal* 2021;**42**:3349–3357.

27. Zhao J, Yang F, Zhuo C, Wang Q, Qu Z, Wang Q, et al. Association of Sleep Duration With Atrial Fibrillation and Heart Failure: A Mendelian Randomization Analysis. *Frontiers in Genetics* 2021;**12**.

28. Arora N, Bhatta L, Skarpsno ES, Dalen H, Åsvold BO, Brumpton BM, et al. Investigating the causal interplay between sleep traits and risk of acute myocardial infarction: a Mendelian randomization study. *BMC Medicine* 2023;**21**:385.

29. UK Biobank: Protocol for a large-scale prospective epidemiological resource. Stockport, Cheshire, UK: UK Biobank Coordinating Centre; 2006. https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us (25 October 2021)

30. Åsvold BO, Langhammer A, Rehn TA, Kjelvik G, Grøntvedt TV, Sørgjerd EP, et al. Cohort Profile Update: The HUNT Study, Norway. *International Journal of Epidemiology* 2023;**52**:e80–e91.

31. Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. *Journal of Sleep Research* 2017;**26**:675–700.

32. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* Nature Publishing Group; 2018;**562**:203–209.

33. Mitchell RE, Hemani G, Dudding T, Corbin L, Harrison S, Paternoster L. UK Biobank Genetic Data: MRC-IEU Quality Control, version 2. 2019. https://data.bris.ac.uk/data/dataset/1ovaau5sxunp2cv8rcy88688v

34. Brumpton BM, Graham S, Surakka I, Skogholt AH, Løset M, Fritsche LG, et al. The HUNT study: A population-based cohort for genetic research. *Cell Genomics* 2022;**2**:100193.

35. Jansen PR, Watanabe K, Stringer S, Skene N, Bryois J, Hammerschlag AR, et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. *Nat Genet* Nature Publishing Group; 2019;**51**:394–403.

36. Dashti HS, Jones SE, Wood AR, Lane JM, Hees VT van, Wang H, et al. Genome-wide association study identifies genetic loci for self-reported habitual sleep duration supported by accelerometer-derived estimates. *Nat Commun* Nature Publishing Group; 2019;**10**:1100.

37. Jones SE, Lane JM, Wood AR, Hees VT van, Tyrrell J, Beaumont RN, et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. *Nat Commun* Nature Publishing Group; 2019;**10**:343.

38. Hosmer DW, Lemeshow S. Confidence Interval Estimation of Interaction. *Epidemiology* 1992;**3**:452.

39. Knol MJ, VanderWeele TJ, Groenwold RHH, Klungel OH, Rovers MM, Grobbee DE. Estimating measures of interaction on an additive scale for preventive exposures. *Eur J Epidemiol* 2011;**26**:433–438.

40. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian randomization. *International Journal of Epidemiology* 2013;**42**:1134–1144.

41. VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P. Methodological Challenges in Mendelian Randomization. *Epidemiology* 2014;**25**:427.

42. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. *Stat Methods Med Res* SAGE Publications Ltd STM; 2017;**26**:2333–2355.

43. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. *Eur J Epidemiol* 2018;**33**:947–952.

44. Minelli C, Del Greco M. F, Plaat DA van der, Bowden J, Sheehan NA, Thompson J. The use of two-sample methods for Mendelian randomization analyses on single large datasets. *International Journal of Epidemiology* 2021;**50**:1651–1659.

45. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International Journal of Epidemiology* 2015;**44**:512–525.

46. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* 2016;**40**:304–314.

47. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *International Journal of Epidemiology* 2017;**46**:1985–1998.

48. Lane JM, Jones SE, Dashti HS, Wood AR, Aragam KG, Hees VT van, et al. Biological and clinical insights from genetics of insomnia symptoms. *Nat Genet* 2019;**51**:387–393.

49. Rees JMB, Foley CN, Burgess S. Factorial Mendelian randomization: using genetic variants to assess interactions. *International Journal of Epidemiology* 2020;**49**:1147–1158.

50. Knol MJ, Tweel I van der, Grobbee DE, Numans ME, Geerlings MI. Estimating interaction on an additive scale between continuous determinants in a logistic regression model. *Int J Epidemiol* 2007;**36**:1111–1118.

51. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *JAMA* 2021;**326**:1614–1621.

52. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. *BMJ* British Medical Journal Publishing Group; 2021;**375**:n2233.

53. Li X, Zhou T, Ma H, Huang T, Gao X, Manson JE, et al. Healthy Sleep Patterns and Risk of Incident Arrhythmias. *Journal of the American College of Cardiology* 2021;**78**:1197–1207.

54. Yang Y, Fan J, Shi X, Wang Y, Yang C, Lian J, et al. Causal associations between sleep traits and four cardiac diseases: a Mendelian randomization study. *ESC Heart Failure* 2022;**9**:3160–3166.

55. Gémes K, Malmo V, Strand LB, Ellekjær H, Loennechen JP, Janszky I, et al. Insomnia symptoms and risk for atrial fibrillation – The HUNT study. *Journal of Sleep Research* **n/a**:e14156.

56. Khawaja O, Sarwar A, Albert CM, Gaziano JM, Djoussé L. Sleep Duration and Risk of Atrial Fibrillation (from the Physicians' Health Study). *The American Journal of Cardiology* 2013;**111**:547–551.

57. Genuardi MV, Ogilvie RP, Saand AR, DeSensi RS, Saul MI, Magnani JW, et al. Association of Short Sleep Duration and Atrial Fibrillation. *Chest* 2019;**156**:544–552.

58. Song Q, Liu X, Hu W, Zhou W, Liu A, Wang X, et al. Long Sleep Duration Is an Independent Risk Factor for Incident Atrial Fibrillation in a Chinese Population: A Prospective Cohort Study. *Sci Rep* Nature Publishing Group; 2017;**7**:3679.

59. Grimaldi D, Carter JR, Van Cauter E, Leproult R. Adverse Impact of Sleep Restriction and Circadian Misalignment on Autonomic Function in Healthy Young Adults. *Hypertension* 2016;**68**:243–250.

60. Castro-Diehl C, Diez Roux AV, Redline S, Seeman T, McKinley P, Sloan R, et al. Sleep Duration and Quality in Relation to Autonomic Nervous System Measures: The Multi-Ethnic Study of Atherosclerosis (MESA). *Sleep* 2016;**39**:1927–1940.

61. Jarrin DC, Ivers H, Lamy M, Chen IY, Harvey AG, Morin CM. Cardiovascular autonomic dysfunction in insomnia patients with objective short sleep duration. *Journal of Sleep Research* 2018;**27**:e12663.

62. Kanagasabai T, Ardern CI. Contribution of Inflammation, Oxidative Stress, and Antioxidants to the Relationship between Sleep Duration and Cardiometabolic Health. *Sleep* 2015;**38**:1905–1912.

63. D'Aurea C, Poyares D, Piovezan RD, Passos GS, Tufik S, Mello MT de. Objective short sleep duration is associated with the activity of the hypothalamic-pituitary-adrenal axis in insomnia. *Arq Neuro-Psiquiatr* Academia Brasileira de Neurologia - ABNEURO; 2015;**73**:516–519.

64. Charloux A, Gronfier C, Lonsdorfer-Wolf E, Piquard F, Brandenberger G. Aldosterone release during the sleep-wake cycle in humans. *American Journal of Physiology-Endocrinology and Metabolism* American Physiological Society; 1999;**276**:E43–E49.

65. Xu Y, Sharma D, Li G, Liu Y. Atrial remodeling: New pathophysiological mechanism of atrial fibrillation. *Medical Hypotheses* 2013;**80**:53–56.

66. Guo Y, Lip GYH, Apostolakis S. Inflammation in Atrial Fibrillation. *Journal of the American College of Cardiology* 2012;**60**:2263–2270.

67. Chen P-S, Chen LS, Fishbein MC, Lin S-F, Nattel S. Role of the Autonomic Nervous System in Atrial Fibrillation. *Circulation Research* American Heart Association; 2014;**114**:1500–1515.

68. Laugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the Risk of Acute Myocardial Infarction. *Circulation* 2011;**124**:2073–2081.

69. Laugsand LE, Strand LB, Platou C, Vatten LJ, Janszky I. Insomnia and the risk of incident heart failure: a population study. *European Heart Journal* 2014;**35**:1382–1393.

70. Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. *Int J Chronobiol* 1976;**4**:97–110.

71. Roenneberg T, Wirz-Justice A, Merrow M. Life between Clocks: Daily Temporal Patterns of Human Chronotypes. *J Biol Rhythms* SAGE Publications Inc; 2003;**18**:80–90.

72. Tudball MJ, Bowden J, Hughes RA, Ly A, Munafò MR, Tilling K, et al. Mendelian randomisation with coarsened exposures. *Genetic Epidemiology* 2021;**45**:338–350.

73. Wade KH, Hamilton FW, Carslake D, Sattar N, Davey Smith G, Timpson NJ. Challenges in undertaking nonlinear Mendelian randomization. *Obesity (Silver Spring)* 2023;**31**:2887–2890.

74. Hamilton FW, Hughes DA, Spiller W, Tilling K, Davey Smith G. Non-linear Mendelian randomization: detection of biases using negative controls with a focus on BMI, Vitamin D and LDL cholesterol. *Eur J Epidemiol* 2024;**39**:451–465.

75. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Medicine* Public Library of Science; 2015;**12**:e1001779.

76. Hernán MA, Hernández-Díaz S, Robins JM. A Structural Approach to Selection Bias. *Epidemiology* 2004;**15**:615.

77. Canan C, Lesko C, Lau B. Instrumental Variable Analyses and Selection Bias. *Epidemiology* 2017;**28**:396.

78. Munafò MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope: when selection bias can substantially influence observed associations. *International Journal of Epidemiology* 2018;**47**:226–235.

79. Gkatzionis A, Burgess S. Contextualizing selection bias in Mendelian randomization: how bad is it likely to be? *International Journal of Epidemiology* 2019;**48**:691–701.

80. Burgess S, Thompson SG, CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. *International Journal of Epidemiology* 2011;**40**:755–764.

81. Moreira MJ, Porter JR, Suarez GA. Bootstrap validity for the score test when instruments may be weak. *Journal of Econometrics* 2009;**149**:52–64.

82. Rothman K, Greenland S, Lash TL. Modern Epidemiology. 3rd Edition. Philadelphia, US: Lippincott Williams & Wilkins; 2007.

83. Kwon Y, Koene RJ, Johnson AR, Lin G-M, Ferguson JD. Sleep, sleep apnea and atrial fibrillation: Questions and answers. *Sleep Medicine Reviews* 2018;**39**:134–142.

84. Zhang L, Hou Y, Po SS. Obstructive Sleep Apnoea and Atrial Fibrillation. *Arrhythm Electrophysiol Rev* 2015;**4**:14–18.

85. Benetó A, Gomez-Siurana E, Rubio-Sanchez P. Comorbidity between sleep apnea and insomnia. *Sleep Medicine Reviews* 2009;**13**:287–293.

86. Krell SB, Kapur VK. Insomnia complaints in patients evaluated for obstructive sleep apnea. *Sleep Breath* 2005;**9**:104–110.

87. The Lancet Respiratory Medicine. Time to wake the giant of obstructive sleep apnoea. *The Lancet Respiratory Medicine* Elsevier; 2020;**8**:1.

88. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* 2014;**23**:R89-98.

89. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. *Genetic Epidemiology* 2016;**40**:597–608.

90. Watanabe K, Jansen PR, Savage JE, Nandakumar P, Wang X, Hinds DA, et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. *Nat Genet* Nature Publishing Group; 2022;**54**:1125–1132.

91. North T-L, Davies NM, Harrison S, Carter AR, Hemani G, Sanderson E, et al. Using Genetic Instruments to Estimate Interactions in Mendelian Randomization Studies. *Epidemiology* 2019;**30**:e33–e35.